2 completed, 2 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Jason Robert Gotlib: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Terminated | Jason Robert Gotlib | 4 | 2015-03-01 | 2018-09-20 |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Completed | Jason Robert Gotlib | 10 | 2013-09-01 | 2019-01-29 |
| Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia Lenalidomide - Anemia, Leukemia | Phase 1 | Terminated | Jason Robert Gotlib | 2 | 2009-11-01 | 2017-08-02 |
| Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Midostaurin - Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell | Phase 2 | Completed | Jason Robert Gotlib | 26 | 2005-03-01 | 2018-09-20 |
Leukemia, Mast-Cell (3) · Mastocytosis, Systemic (3) · Aggression (1) · Anemia (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Brentuximab Vedotin (1) · Lenalidomide (1) · ibrutinib (1) · midostaurin (1)
United States (4)
Jason Gotlib (2)
PMID 27355533, PMID 28744009, PMID 31350306
P30CA124435 (1)